Eli Lilly

Zydus Cadila and Eli Lilly sign drug discovery pact

Leading cardiovascular research firm, Eli Lilly and Ahmedabad-based drug maker, Zydus Cadila signed a pact to develop and research new drugs for six years. The deal is aimed to increase productivity in drug discovery and development by using the expertise of both firms in the field of medicine.

Nicholas R&D Unit Signs Drug Development Pact With Eli Lilly

Nicholas Piramal India Ltd has announced that its research & development (R&D) unit has signed up a drug development deal with Eli Lilly & Co. (LLY).

In this new contract, NPIL Research & Development Ltd. and Lilly will separately execute early clinical growth of two different experimental drugs targeted at the same therapeutic area, the company informed

NPIL Research & Development could obtain around $110 million in milestone payments in addition to royalties on sales.

No details on the deal were available immediately.